ArcanaBio joins BII’s Deep Tech Lab Quantum - a Novo Nordisk supported initiative with the vision for world-class innovation based on quantum science
Copenhagen, 1 Sept 2024 – ArcanaBio, a pioneering biotech company, is proud to announce its selection for funding by Denmark’s BioInnovation Institute (BII), supported by the Novo Nordisk Foundation. ArcanaBio will join BII’s Deep Tech Lab – Quantum program in Copenhagen from September 2024.
“We are delighted and honoured to receive this funding and to be selected to join this prestigious quantum initiative,” said Kristjan Gunnarsson, CEO of ArcanaBio. “We are at the forefront of a new biosensor revolution with a patent-pending, label-free detection technology that has been a long-sought-after advancement in proteomics. Our novel platform has potential both to enable high throughput laboratories to offer a wider range of biomarker detection services at lower cost and empower individuals to proactively monitor their health by integrating frequent, reference quality testing into their everyday lives.”
“The goal here is to rethink diagnostics. Building a new capability to track proteome dynamics over time can provide powerful real-time insights into health status, disease progression and epidemiology,” commented Daniel Oskarsson, CTO of ArcanaBio, “Ultimately this can serve as an enabler of preventive healthcare — a solution to the challenge of rising societal costs.”
Leveraging novel nano-photonics technology, ArcanaBio is developing an innovative label-free liquid biopsy solution. This solution aims to transform health status monitoring and pathogen detection by enabling faster, cheaper, and higher-throughput testing. This new proteomics technology has the potential to drive the next generation of time-series biomarker testing, support new research in proteomics, and foster new partnerships. The platform will enable both more comprehensive laboratory services at a lower cost and bring reference-grade diagnostics to the home.
About ArcanaBio
ArcanaBio is a leading biotech company dedicated to developing next-generation diagnostic technologies that are both rapid and accessible. Now part of the BioInnovation Institute’s Deep Tech Lab – Quantum program, ArcanaBio leverages Denmark’s global leadership in quantum technology. With a focus on nano-photonics and biosensors, ArcanaBio brings laboratory-grade testing into everyday environments, empowering individuals to take charge of their health. For more information, visit www.arcanabio.com.
About BioInnovation Institute
The BioInnovation Institute (BII), an initiative by the Novo Nordisk Foundation, is a non-profit international enterprise foundation focused on accelerating world-class life science innovation. BII supports early-stage life science startups, fostering the development of new solutions that benefit society. The Deep Tech Lab – Quantum, supported by BII, is Denmark’s official NATO DIANA accelerator site, leveraging the country’s leadership in quantum science to drive dual-use innovations across the life science and defense industries. For more information, visit bii.dk.
